Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy

Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have been approved for the treatment of a variety of cancers. However, the efficacy of antibody-based ICIs could be further improved by mitigating anti-drug antibodies, proteolytic cleavage, and on-target off-tumor toxicity. One strategy for ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yundi, Wang, Lixue, Zheng, Mingfeng, Zhu, Chuandong, Wang, Guosheng, Xia, Yiqiu, Blumenthal, Ethan J., Mao, Wenjun, Wan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586263/
https://www.ncbi.nlm.nih.gov/pubmed/34820569
http://dx.doi.org/10.1016/j.bioactmat.2021.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586263/
https://www.ncbi.nlm.nih.gov/pubmed/34820569
http://dx.doi.org/10.1016/j.bioactmat.2021.07.012

Ejemplares similares